The estimated Net Worth of Volker Knappertz is at least $4.05 Million dollars as of 27 February 2024. Mr. Knappertz owns over 4,930 units of GW Pharmaceuticals stock worth over $22,339 and over the last 6 years he sold GWPH stock worth over $1,028,595. In addition, he makes $3,001,820 as Chief Medical Officer at GW Pharmaceuticals.
Sign up
Mr. Knappertz GWPH stock SEC Form 4 insiders trading
Volker has made over 17 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 4,930 units of GWPH stock worth $30,073 on 27 February 2024.
The largest trade he's ever made was exercising 133,620 units of GW Pharmaceuticals stock on 18 May 2020 worth over $9,353. On average, Volker trades about 17,712 units every 83 days since 2019. As of 27 February 2024 he still owns at least 319,128 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Knappertz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Volker Knappertz biography
Volker Knappertz serves as Chief Medical Officer of the Company. Dr. Knappertz has over 25 years of clinical trial experience and 17 years of pharmaceutical drug development experience, holding leadership positions with responsibilities for managing international clinical trial and medical affairs programs. Since joining the Company, Mr. Knappertz oversaw the filing and approval of Epidiolex and the global development efforts of cannabinoids. Most recently, as the vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva Pharmaceuticals (“Teva”), a multinational pharmaceutical company, Dr. Knappertz oversaw multiple regulatory submissions and approvals in the United States, Canada, Europe and Japan. Prior to joining Teva in 2012, Dr. Knappertz served in clinical and medical roles in CNS, CV, and biologics at Bayer Pharmaceuticals, a multinational pharmaceutical and life sciences company, and AstraZeneca, a research-based biopharmaceutical company. Dr. Knappertz is a U.S. Board certified neurologist who received his residency training at Yale University where he served as chief resident and was fellowship trained at Wake Forest University. He received his clinical scientist training and M.D. as well as a doctorate degree in research on glioblastoma from the University at Cologne in Germany.
What is the salary of Volker Knappertz?
As the Chief Medical Officer of GW Pharmaceuticals, the total compensation of Volker Knappertz at GW Pharmaceuticals is $3,001,820. There are 2 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is Volker Knappertz?
Volker Knappertz is 54, he's been the Chief Medical Officer of GW Pharmaceuticals since 2017. There are 9 older and 3 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Volker Knappertz's mailing address?
Volker's mailing address filed with the SEC is #140, 14315-118 AVENUE, , EDMONTON, A0, T5L 4S6.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble, and Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. Knappertz stock trades at Aurinia Pharmaceuticals Inc and GW Pharmaceuticals
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America